CSF ACR 2023 axSpA Highlights
- No tags were found...
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
<strong>ACR</strong> <strong>2023</strong><br />
Congress Preview<br />
Axial Spondyloarthritis<br />
Faculty Introduction<br />
Dear Colleagues,<br />
Welcome to this year’s selection of <strong>ACR</strong> abstracts on <strong>axSpA</strong> and my ‘<strong>Highlights</strong>’. Here we have selected a<br />
variety of abstracts that cover a range of key topics in the management of axial spondyloarthritis.<br />
On Sunday, the <strong>axSpA</strong> session ‘Spondyloarthritis Including Psoriatic Arthritis – Treatment: AxSpA Poster I’<br />
offers a number of noteworthy presentations, with data highlighted by Phillip Mease (0510), and Marina Nighat<br />
Magrey (0525) on bimekizumab, including its efficacy in TNFi naïve compared to TNFi-IR patients. There are<br />
also posters on the subject of tapering tofacitinib (0534), long-term follow-up of the DESIR cohort (0512),<br />
and an oral presentation on the analysis of the SPACE cohort assessing the diagnostic performance of<br />
different MRI-lesion definitions (0843). Make sure to have a look at them and the other posters I recommend<br />
when you can.<br />
Monday includes presentations from Denis Poddubnyy (1392) on the interim results of a nationwide<br />
telemedicine project aiming at improving the diagnostic accuracy in <strong>axSpA</strong>, along with the latest data from<br />
the SELECT-AXIS 1 and SELECT-AXIS 2 trials highlighted by Victoria Navarro-Compan (1397).<br />
Finally, Tuesday features an abstract session reporting the latest Phase 3 efficacy and safety data for<br />
secukinumab IV (2545) by Atul Deodhar, novel research by Martin Rudwaleit into uveitis rates in patients<br />
treated with bimekizumab (2548), and a post-hoc analysis of the COAST-V trial into the effect of ixekizumab<br />
treatment on MRI structural lesions (2549) by Walter Maksymowych. These sessions promise to provide great<br />
updates on the treatment and management of patients with <strong>axSpA</strong>. You can find more details in this brochure.<br />
As always, thank you for your continued support. We hope you have a fantastic time at <strong>ACR</strong> <strong>2023</strong>!<br />
Kind regards,<br />
Sofia Ramiro<br />
PS. Make sure you get all the insights from this <strong>ACR</strong> by downloading our other highlights brochures, and if<br />
you want to see the top picks for Lupus head on over to www.lupus-forum.com where you’ll find the top<br />
<strong>ACR</strong> picks and their top abstracts in the field of lupus therapeutics.<br />
Register for FREE content at<br />
www.cytokinesignalling.com<br />
Follow us at:<br />
Cytokine Signalling Forum<br />
SPONSORSHIP AND UNRESTRICTED<br />
EDUCATIONAL GRANTS FROM<br />
DEVELOPED UNDER<br />
THE AUSPICES OF THE
KEY:<br />
H<br />
<strong>Highlights</strong><br />
ABSTRACT SESSION<br />
POSTER SESSION<br />
SCIENTIFIC SESSION<br />
Key Presentations<br />
Sunday, 12 November <strong>2023</strong><br />
09:00–<br />
10:00<br />
12S114<br />
09:00–<br />
11:00<br />
0161<br />
09:00–<br />
11:00<br />
0338<br />
09:00–<br />
11:00<br />
0495<br />
09:00–<br />
11:00<br />
0510<br />
0511<br />
SPONDYLOARTHRITIS (SPA) INCLUDING<br />
PSORIATIC ARTHRITIS (PSA)<br />
Chairs: Marina Magrey, Abin Puravath, Jessica Walsh<br />
Pearls & Pitfalls in Diagnosing Non-Radiographic<br />
Axial Spondyloarthritis<br />
Lianne Gensler, Mark Hwang & Alexis Ogdie<br />
HEALTH SERVICES RESEARCH POSTER 1<br />
Differences and Similarities Between the EULAR/<br />
ASAS-EULAR Recommendations and National<br />
Recommendations for Treatment of Patients<br />
with Psoriatic Arthritis and Axial Spondyloarthritis<br />
Across Europe<br />
Brigitte Michelsen<br />
PATIENT OUTCOMES, PREFERENCES, &<br />
ATTITUDES POSTER I<br />
Comparative Disease Burden in Patients with<br />
Rheumatoid Arthritis, Psoriatic Arthritis or<br />
Ankylosing Spondylitis: Data from COVAD<br />
Patient-reported E-survey<br />
Diego Benavent<br />
SPONDYLOARTHRITIS INCLUDING<br />
PSORIATIC ARTHRITIS – DIAGNOSIS,<br />
MANIFESTATIONS, & OUTCOMES<br />
POSTER I: PSA<br />
Prevalence of Undiagnosed Inflammatory<br />
Bowel Disease in Patients with Spondyloarthritis:<br />
EISER Study<br />
Zulema Plaza<br />
SPONDYLOARTHRITIS INCLUDING<br />
PSORIATIC ARTHRITIS – TREATMENT:<br />
AXSPA POSTER I<br />
Bimekizumab Treatment Improved Key<br />
Patient-Reported Symptoms of Axial<br />
Spondyloarthritis Including Spinal Pain,<br />
Fatigue, and Morning Stiffness: 52-Week<br />
Results from Two Phase 3 Studies<br />
Philip J. Mease<br />
Long-term Safety and Tolerability of Bimekizumab<br />
in Patients with Axial Spondyloarthritis and Psoriatic<br />
Arthritis: Results from Pooled Phase 2b/3 Studies<br />
Phillip J. Mease<br />
H<br />
0512<br />
0516<br />
0518<br />
0519<br />
0520<br />
0521<br />
0522<br />
0523<br />
0525<br />
0526<br />
Factors Associated with Treatment<br />
Pathways in Early Axial Spondyloarthritis:<br />
A Multistate Analysis of the 10-year Follow-up<br />
of the DESIR Cohort<br />
Elodie Portier<br />
Drivers of Treatment Intensification in Patients with<br />
Axial Spondyloarthritis and High Disease Activity:<br />
Results from a Clinical Practice Registry<br />
Casper Webers<br />
Tofacitinib Efficacy and Safety in Patients with<br />
Ankylosing Spondylitis by Baseline C-Reactive<br />
Protein Levels: A Post Hoc Analysis<br />
Atul Deodhar<br />
Long-Term Safety and Efficacy of Bimekizumab<br />
in Patients with Active Ankylosing Spondylitis:<br />
5-Year Results from a Phase 2b Study and Its<br />
Open-Label Extension<br />
Atul Deodhar<br />
How Do Early Disease Activity and Early Clinical<br />
Response Associate with Long-Term Outcomes with<br />
Ixekizumab in Radiographic Axial Spondyloarthritis?<br />
Sofia Ramiro<br />
Work Productivity Improved in Patients with Axial<br />
Spondyloarthritis Receiving Bimekizumab Treatment<br />
over 52 Weeks: Results from Two Phase 3 Studies<br />
Martin Rudawaleit<br />
Effect of Secukinumab versus Adalimumab<br />
Biosimilar on Radiographic Progression in<br />
Patients with Radiographic Axial Spondyloarthritis:<br />
Results from Subgroup Analyses by Baseline<br />
Syndesmophytes and C-reactive Protein Status<br />
Xenofon Baraliakos<br />
Bimekizumab Maintained Stringent Clinical<br />
Responses Through Week 52 in Patients with Axial<br />
Spondyloarthritis: Results from Two Phase 3 Studies<br />
Fabian Profit<br />
Bimekizumab Achieved Sustained<br />
H<br />
Improvements in Efficacy Outcomes in<br />
Patients with Axial Spondyloarthritis, Regardless<br />
of Prior TNF Inhibitor Treatment: Week 52 Pooled<br />
Results from Two Phase 3 Studies<br />
Marina Nighat Magrey<br />
Bimekizumab Improved Physical Function and<br />
Health-Related Quality of Life in Patients with<br />
Axial Spondyloarthritis: 52-Week Results from<br />
Two Phase 3 Studies<br />
Maureen Dubreuil<br />
H
KEY:<br />
H<br />
<strong>Highlights</strong><br />
ABSTRACT SESSION<br />
POSTER SESSION<br />
SCIENTIFIC SESSION<br />
0529<br />
0530<br />
0533<br />
0534<br />
0539<br />
0540<br />
0542<br />
12:00–<br />
13:00<br />
12S127<br />
14:00–<br />
15:30<br />
0739<br />
Sex-dependent Differences in Disease<br />
Characteristics Do Not Influence Effectiveness<br />
of Secukinumab Therapy in Patients with Active<br />
Axial Spondyloarthritis in a Non-Interventional<br />
Trial (AQUILA)<br />
Michaela Koehm<br />
Impact of Upadacitinib on Wearable Device-<br />
Measured Physical Activity in Patients with<br />
Ankylosing Spondylitis from the SELECT-AXIS 2 Trial<br />
Jeffery Curtis<br />
Remission in Axial Spondyloarthritis: Is There a<br />
Difference Between NSAIDs and b/tsDMARDs in<br />
Daily Practice?<br />
Adrien Nzeusseu Toukap<br />
Tapering Tofacitinib for Axial Spondyloarthritis<br />
in Remission or Low-disease Activity State<br />
Pankti Mehta<br />
Impact of Extreme Baseline BASDAI and/or<br />
Maastricht AS Enthesitis Score on Treatment<br />
Response to Upadacitinib in Patients with Axial<br />
Spondyloarthritis<br />
Maxime Dougados<br />
The Impact of Baseline BMI and Physical Activity<br />
on Upadacitinib Treatment Response: A Post Hoc<br />
Analysis of Patients with Ankylosing Spondylitis<br />
from the SELECT-AXIS 2 Study<br />
Angela Crowley<br />
Two-Year Treatment Adherence and Clinical<br />
Response to Secukinumab Compared to TNF<br />
Inhibitors in Axial and Peripheral Spondyloarthritis<br />
Patients: A Single-Center Prospective<br />
Observational Study<br />
Irini Flouri<br />
RHEUMATOID ARTHRITIS<br />
Chairs: Percio Gulko, Anne-Marie Malfait<br />
No Pain and Much to Gain: Mechanisms and<br />
Targets of Pain in Rheumatic Diseases<br />
Ru-Rong Ji, Rachel Miller & Theodore Price<br />
EPIDEMIOLOGY AND PUBLIC HEALTH I<br />
Major Adverse Cardiovascular Event and<br />
Venous Thromboembolism Risk Comparing<br />
Advanced Therapies Among Individuals with<br />
Axial Spondylarthritis and Psoriatic Arthritis<br />
Sali Merjanah<br />
H<br />
16:00–<br />
17:00<br />
0843<br />
0845<br />
16:00–<br />
17:00<br />
12S155<br />
SPONDYLOARTHRITIS INCLUDING<br />
PSORIATIC ARTHRITIS – DIAGNOSIS,<br />
MANIFESTATIONS, & OUTCOMES I: AXSPA<br />
Predictive Validity of Data-driven Definitions<br />
for Active and Structural Lesions in the SI<br />
Joints Typical for Axial SpA: A 2-year Follow-up<br />
in the SPondyloArthritis Caught Early Cohort<br />
Liese de Bruin<br />
The Yield of Repeated Assessments in Chronic<br />
Back Pain Patients Suspected of Early Axial<br />
Spondyloarthritis: Two-year Data from the<br />
SPondyloArthritis Caught Early (SPACE) Cohort<br />
Mary Lucy Marques<br />
EPIDEMIOLOGY, HEALTH POLICY<br />
AND OUTCOMES<br />
Chairs: Kristi Kuhn, Michael Weisman<br />
FDA Update on Safety Issues in the Treatment of<br />
Rheumatic Diseases<br />
Eric Gapud, Nadia Habal & Anil Rajpal<br />
Monday, 13 November <strong>2023</strong><br />
09:00–<br />
11:00<br />
1383<br />
1390<br />
1392<br />
1397<br />
1410<br />
SPONDYLOARTHRITIS INCLUDING<br />
PSORIATIC ARTHRITIS – DIAGNOSIS,<br />
MANIFESTATIONS, & OUTCOMES POSTER II:<br />
IMAGING & AS<br />
Long-term Association Between Physical Activity<br />
and Global Functioning in Patients with <strong>axSpA</strong>:<br />
Results of a 2 Year Prospective Study<br />
Kwi Young Kang<br />
Prediction of Low Disease Activity in Patients<br />
with Ankylosing Spondylitis Treated with<br />
Secukinumab in Real World – Data from a<br />
German Observational Study<br />
Uta Kiltz<br />
Improving the Diagnostic Accuracy in Axial<br />
Spondyloarthritis: Interim Results of a<br />
Nationwide Telemedicine Project<br />
Denis Poddubnyy<br />
Sustainability of Clinical Response at<br />
Week 52 to Upadacitinib Among Patients<br />
with Axial SpA: Data from the SELECT-AXIS 1<br />
and SELECT-AXIS 2 Trials<br />
Victoria Navarro-Compan<br />
The Use of the ASAS Referral Criteria Together<br />
with Increased Education and Training of Its<br />
Use Improves Delay to Diagnosis of Axial<br />
Spondyloarthritis<br />
Antoni Chan<br />
H<br />
H<br />
H
KEY:<br />
H<br />
<strong>Highlights</strong><br />
ABSTRACT SESSION<br />
POSTER SESSION<br />
SCIENTIFIC SESSION<br />
1411<br />
09:00–<br />
11:00<br />
1417<br />
1436<br />
Prevalence of Early Axial Spondyloarthritis in the<br />
Be-GIANT Cohort Based on the ASAS Consensus<br />
Definition of Early Axial Spondyloarthritis<br />
Gaelle Varkas<br />
SPONDYLOARTHRITIS INCLUDING<br />
PSORIATIC ARTHRITIS – TREATMENT<br />
POSTER II: SPA<br />
Do Long-term Patient-reported Outcomes<br />
Improve Similarly in Psoriatic Arthritis and Axial<br />
Spondyloarthritis Patients Treated with Secukinumab?<br />
Results from the EuroSpA Collaboration<br />
Marion Pons<br />
Secukinumab Demonstrates a Consistent Safety<br />
Profile in Patients with Psoriasis, Psoriatic Arthritis<br />
and Axial Spondyloarthritis: Updated Pooled Safety<br />
Analysis from Clinical Trials<br />
Atul Deodhar<br />
Tuesday, 14 November <strong>2023</strong><br />
09:00–<br />
11:00<br />
2145<br />
09:00–<br />
11:00<br />
2196<br />
2198<br />
RA – TREATMENTS POSTER III<br />
Patterns of Use, Effectiveness, Persistence and<br />
Cardiovascular Risk in Patients with Rheumatic<br />
Diseases Treated with Upadacitinib in a Real-world<br />
Setting. UPAREAL Study<br />
Alicia Garcia Dorta<br />
SPONDYLOARTHRITIS INCLUDING<br />
PSORIATIC ARTHRITIS – DIAGNOSIS,<br />
MANIFESTATIONS, & OUTCOMES<br />
POSTER III: SPA<br />
Females with Axial Spondyloarthritis Report Higher<br />
Burden of Disease and Worse Patient-reported<br />
Outcomes. Results from the International Map of<br />
Axial Spondyloarthritis (IMAS)<br />
Victoria Navarro-Compan/Marco Garrido-Cumbrera<br />
Which Factors Are Associated with Clinically<br />
High Disease Activity in Axial Spondyloarthritis?<br />
Results from the International Map of Axial<br />
Spondyloarthritis (IMAS)<br />
Marco Garrido-Cumbrera<br />
2199<br />
16:00–<br />
17:30<br />
2545<br />
2548<br />
2549<br />
Four-year Secukinumab Treatment Outcomes<br />
in Axial Spondyloarthritis and Psoriatic Arthritis<br />
Patients Treated in Routine Care: Results from the<br />
EuroSpA Collaboration<br />
Marion Pons<br />
SPONDYLOARTHRITIS INCLUDING<br />
PSORIATIC ARTHRITIS – TREATMENT III:<br />
AXSPA<br />
Efficacy and Safety of Intravenous<br />
Secukinumab for the Treatment of Active<br />
Axial Spondyloarthritis: Results from a<br />
Randomized, Double-Blind, Phase 3 Study<br />
Atul Deodhar<br />
Low Uveitis Rates in Patients with Axial<br />
Spondyloarthritis Treated with Bimekizumab:<br />
Pooled Results from Phase 2b/3 Trials<br />
Martin Rudwaleit<br />
Effect of Ixekizumab Treatment on MRI<br />
Structural Lesions in the Sacroiliac<br />
Joints of Patients with Radiographic Axial<br />
Spondyloarthritis; A Post-hoc Analysis of a<br />
Placebo and Active Controlled RCT<br />
Walter Maksymowych<br />
Satellite Symposia<br />
SUNDAY, 12 NOVEMBER <strong>2023</strong><br />
11:30–<br />
12:15<br />
Treating Patients with PsA and AS Today & Tomorrow<br />
Sponsor: Eli Lilly<br />
Chairs: Alvin Wells, Ara Dikranian, Jill Zouzoulas<br />
H<br />
H<br />
H<br />
Register for FREE content at www.cytokinesignalling.com<br />
DEVELOPED UNDER<br />
THE AUSPICES OF THE<br />
Follow us at:<br />
Cytokine Signalling Forum
Change language